Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 49/100

Q3 2021 Redhill Biopharma Ltd Earnings Call Transcript

Nov 30, 2021 / 01:30PM GMT
Release Date Price: €105.2 (+5.20%)
Operator

Good day, and thank you for standing by. Welcome to the RedHill Biopharma's Third Quarter 2021 Results Financial Conference Call. (Operator Instructions) At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Micha Ben-Chorin, Chief Financial Officer; Gilead Raday, Chief Operating Officer; Guy Goldberg, Chief Business Officer; Adi Frish, Chief Corporate and Business Development Officer; Rob Jackson, Senior Vice President, Sales and Marketing; Bob Gilkin, Senior VP, Market Access and Trade Relations; and Dr. June Almenoff, Chief Medical Officer. Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.

Alexandra Okmian
RedHill Biopharma Ltd. - Senior Business Development & IR Manager

Thank you, Brian. This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot